Autopsy report · NCT05605093

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

“DSMB closed due to futility.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 10 months before it stopped.
• 602 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

University of Minnesota

Sponsor type

University, hospital or other

Conditions

COVID-19

Interventions

Shionogi Protease Inhibitor (S-217622); placebo

Participants

602

Sites

187

Countries

Argentina, Australia, Brazil, Denmark, Georgia, Germany, Greece, Japan, Mexico, Nigeria, Peru, Poland and more

Trials that died the same way

• Helping HIV Infected Patients in South Africa Adhere to Drug Regimens
  “DSMB stopped trial for futility” (79% match in meaning)
• LCI Apheresis to Obtain Plasma or White Blood Cells
  “Closed by the Sponsor/DSMB/IRB” (67% match in meaning)
• Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
  “DSMB determined, due to higher than expected risk/safety concerns, study should be closed.” (66% match in meaning)
• A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy
  “Upon recommendation of DSMB” (65% match in meaning)
• Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO
  “DSMB recommendation (futility)” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.